Yitong Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yitong Gao has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Can Xiao
Jiang Su Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China
1 shared publication - Mengchen Lu
Department of Medicinal Chemistry, College of Pharmaceutical Sciences, Soochow University Medical College, Suzhou 215123, China
1 shared publication - Qian Wu
School of Pharmacy, Suzhou Medical College, Soochow University, Suzhou 215006, China
1 shared publication - Qidong You
China Pharmaceutical University
1 shared publication - Yabing Xin
School of Pharmacy, Suzhou Medical College, Soochow University, Suzhou 215006, China
1 shared publication - Zhengyu Jiang
China Pharmaceutical University
1 shared publication
Latest Publications
- Open Access
Scaffold Hopping-Guided Design of Novel PIM-1 Inhibitors with Anticancer Activities
PIM kinases, as members of the serine/threonine kinase family, regulate key cellular processes such as proliferation, apoptosis, and metabolism by phosphorylating multiple substrates, making them important therapeutic targets for cancer treatment. In this study, we reported a series of structurally novel PIM-1 kinase inhibitors based on a scaffold-hopping strategy. After multiple rounds of structural optimization, the highly active compound C2 was obtained, exhibiting an IC50 of 33.02 ± 1.31 nM against PIM-1 kinase. Molecular docking results revealed that compound C2 stably bound to the hydrophobic cavity of the PIM-1 protein and formed hydrogen bond interactions with polar residues in the hinge region, thereby effectively inhibiting kinase activity. In vitro antitumor assessment demonstrated significant proliferation inhibition of the hematological tumor cell line MM.1S (IC50 = 1.87 μM), comparable to the positive control SGI-1776 (IC50 = 1.71 μM). In addition, compound C2 possessed favorable drug-like properties and excellent stability in simulated gastrointestinal fluids and rat plasma. This study provides promising lead compounds for the development of novel PIM-1-targeted anticancer drugs, which can be further optimized.
Open AccessScaffold Hopping-Guided Design of Novel PIM-1 Inhibitors with Anticancer Activities
PIM kinases, as members of the serine/threonine kinase family, regulate key cellular processes such as proliferation, apoptosis, and metabolism by phosphorylating multiple substrates, making them important therapeutic targets for cancer treatment. In this study, we reported a series of structurally novel PIM-1 kinase inhibitors based on a scaffold-hopping strategy. After multiple rounds of structural optimization, the highly active compound C2 was obtained, exhibiting an IC50 of 33.02 ± 1.31 nM against PIM-1 kinase. Molecular docking results revealed that compound C2 stably bound to the hydrophobic cavity of the PIM-1 protein and formed hydrogen bond interactions with polar residues in the hinge region, thereby effectively inhibiting kinase activity. In vitro antitumor assessment demonstrated significant proliferation inhibition of the hematological tumor cell line MM.1S (IC50 = 1.87 μM), comparable to the positive control SGI-1776 (IC50 = 1.71 μM). In addition, compound C2 possessed favorable drug-like properties and excellent stability in simulated gastrointestinal fluids and rat plasma. This study provides promising lead compounds for the development of novel PIM-1-targeted anticancer drugs, which can be further optimized.